Five years after Penn and Novartis made history with the FDA approval of Kymriah, the first Car-T cell therapy, a recent study has shown the long-term impact of the medication on patient remission rates.
According to Novartis, over the past five years, Kymriah has yielded a five-year relapse-free survival rate of 44% for patients who previously faced a five-year survival rate of less than 10%. These data provide profound hope to children and young adults affected by relapsed or refractory B-cell Acute lymphoblastic leukemia (ALL), as relapse after a five year period is rare.
Read the full article using the following link: